A Prospective, Randomized Clinical Trial Evaluating INTIBIA, an Investigational Implantable Tibial Nerve Stimulator, Through 24-Months (INTIBIA Pivotal Study IU024)
Overview
- Phase
- Not Applicable
- Intervention
- INTIBIA Therapeutic
- Conditions
- Urinary Incontinence, Urge
- Sponsor
- Coloplast A/S
- Enrollment
- 208
- Locations
- 22
- Primary Endpoint
- Response Rate
- Status
- Active, not recruiting
- Last Updated
- 3 months ago
Overview
Brief Summary
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Detailed Description
All eligible subjects will be implanted with the INTIBIA device. Subjects will be randomized to either INTIBIA therapeutic or INTIBIA non-therapeutic in a 2:1 ratio for the first 3 months of the study, at which point all subjects will receive therapeutic stimulation. Subjects will complete voiding diaries and questionnaires at Baseline and prior to each follow-up visit, which will occur at Months 3, 6, 12, and 24. Subjects will be offered to keep the device or have it explanted at the end of the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women or men 22-80 years of age
- •Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period
- •Greater than or equal to 6-month history of UUI diagnosis
- •Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management)
- •Willing to abstain from OAB medications for the duration of the study
- •Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires
- •Ambulatory and able to use the toilet independently and without difficulty
- •Willing and capable of providing informed consent
- •Willing and able to complete all procedures and follow-up visits indicated in the protocol
Exclusion Criteria
- •Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire
- •Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year
- •Have post-void residual urine volume \>30% of total voided volume
- •Inadequate skin integrity, any evidence of an infection, or lower leg edema limiting placement of device per physician discretion
- •Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject
- •Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation \[PTNS\] or sacral nerve stimulation \[SNS\])
- •History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain)
- •An active implantable electronic device regardless of whether stimulation is ON or OFF
- •Treatment of urinary symptoms with botulinum toxin therapy within six (6) months
- •Any neurological condition that could interfere with normal bladder or tibial nerve function, including debilitating stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia)
Arms & Interventions
INTIBIA Therapeutic
Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study.
Intervention: INTIBIA Therapeutic
INTIBIA Non-Therapeutic
Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study.
Intervention: INTIBIA Non-Therapeutic
Outcomes
Primary Outcomes
Response Rate
Time Frame: 12 Months
≥50% reduction in UUUI episodes in the INTIBIA therapeutic group
Response Rate
Time Frame: 3 Months
≥50% reduction in UUI episodes between INTIBIA therapeutic and INTIBIA non-therapeutic
Secondary Outcomes
- Daily Voids(3 Months)
- Urgency Score(3 Months)